CW January 2003
Volume 12Issue Number 1 January 2003 ISSN 10593802 Peptide Vaccine Builds Immunity to Leukemia CellsSeveral decades after vaccines for cancer were first proposed, a targeted therapy is now being tested on leukemia patients. The first vaccine targeted to acute myelogenous leukemia (AML) can elicit highly active tissue-specific immunity against leukemia cells and induce remission, according to a small pilot study.
Go to Previous Page Go to Next Page Source & Additional Reading J. Molldrem, American Society of Hematology Annual Meeting. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW January 2003Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
